Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by SPC Financial Inc.

SPC Financial Inc. reduced its position in Axon Enterprise, Inc. (NASDAQ:AXON) by 4.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,735 shares of the biotechnology company’s stock after selling 74 shares during the quarter. SPC Financial Inc.’s holdings in Axon Enterprise were worth $511,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. ICA Group Wealth Management LLC acquired a new stake in shares of Axon Enterprise during the 4th quarter valued at approximately $26,000. Blue Trust Inc. raised its holdings in shares of Axon Enterprise by 987.5% during the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 79 shares during the period. Trivant Custom Portfolio Group LLC bought a new position in shares of Axon Enterprise in the 1st quarter worth about $31,000. First PREMIER Bank acquired a new position in shares of Axon Enterprise in the 1st quarter valued at about $33,000. Finally, Rise Advisors LLC grew its position in shares of Axon Enterprise by 49.0% during the 1st quarter. Rise Advisors LLC now owns 143 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 47 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analysts Set New Price Targets

AXON has been the topic of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $400.00 target price on shares of Axon Enterprise in a report on Wednesday, August 7th. JMP Securities upped their price objective on Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Robert W. Baird increased their target price on Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Jefferies Financial Group started coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price target for the company. Finally, Bank of America began coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price objective on the stock. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus price target of $365.38.

Axon Enterprise Trading Down 0.1 %

Axon Enterprise stock opened at $399.22 on Wednesday. Axon Enterprise, Inc. has a 12-month low of $190.01 and a 12-month high of $400.78. The stock has a market capitalization of $30.13 billion, a PE ratio of 116.73, a price-to-earnings-growth ratio of 10.59 and a beta of 0.94. The firm has a 50 day simple moving average of $359.52 and a 200-day simple moving average of $321.46. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.18. The company had revenue of $504.00 million for the quarter, compared to analysts’ expectations of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The firm’s revenue for the quarter was up 34.5% on a year-over-year basis. During the same period last year, the firm earned $0.80 EPS. As a group, equities research analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Brittany Bagley sold 4,338 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the completion of the transaction, the chief financial officer now owns 98,825 shares in the company, valued at approximately $37,449,733.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CFO Brittany Bagley sold 4,338 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the completion of the sale, the chief financial officer now directly owns 98,825 shares of the company’s stock, valued at $37,449,733.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Julie A. Cullivan sold 900 shares of Axon Enterprise stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $353.53, for a total transaction of $318,177.00. Following the completion of the transaction, the director now owns 3,653 shares in the company, valued at approximately $1,291,445.09. The disclosure for this sale can be found here. Over the last three months, insiders have sold 318,091 shares of company stock worth $115,706,734. 6.10% of the stock is owned by corporate insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.